| Trial ID: | L5512 |
| Source ID: | NCT04447859
|
| Associated Drug: |
Semaglutide
|
| Title: |
16-week Flexible vs. 8-week Semaglutide Titration
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes type2
|
| Interventions: |
DRUG: Semaglutide|OTHER: label recommended titration
|
| Outcome Measures: |
Primary: Gastrointestinal adverse events (GI-AEs), % occurrence of GI-AEs over time (pooled nausea, vomiting, diarrhea and every component alone), 16 weeks - from visit one to visit seven (and in each visit alone) |
|
| Sponsor/Collaborators: |
Sponsor: Tel-Aviv Sourasky Medical Center
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2020-02-23
|
| Completion Date: |
2022-09-10
|
| Results First Posted: |
|
| Last Update Posted: |
2020-06-25
|
| Locations: |
Tel-Aviv Medical Center, Tel Aviv, Israel
|
| URL: |
https://clinicaltrials.gov/show/NCT04447859
|
